NCT04126525View on ClinicalTrials.gov

Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

June 18, 2019

Primary Completion Date

October 28, 2021

Study Completion Date

November 30, 2026

Conditions
Breast Cancer Female
Interventions
DRUG

Pyrotinib

dual HER2 blockade in the neoadjuvant setting

Trial Locations (1)

Unknown

Renji Hospital, Shanghai

All Listed Sponsors
lead

RenJi Hospital

OTHER

NCT04126525 - Neoadjuvant Study of Pyrotinib in HER-2 Positive Breast Cancer | Biotech Hunter | Biotech Hunter